Used in targeted cancer therapies, particularly for tumors overexpressing the AXL receptor, such as non-small cell lung cancer, pancreatic cancer, and acute myeloid leukemia. Binds specifically to AXL, blocking its activation and downstream signaling pathways involved in tumor growth, metastasis, and drug resistance. Enhances the effects of chemotherapy and other targeted agents by sensitizing cancer cells. Investigated in combination with immune checkpoint inhibitors to improve anti-tumor immune responses. Also applied in diagnostic settings to detect AXL expression in tumor tissues, aiding in patient selection for AXL-targeted treatments.